Jul 21, 2020. OPK stock was acquired by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Rafferty Asset Management LLC, Swiss National Bank, AE Wealth Management LLC, Creative Planning, Virtu Financial LLC, Envestnet Asset Management Inc., and WINTON GROUP Ltd. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Anthony J Japour, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel, and Steven D Rubin. Get Our PREMIUM Forecast Now, from ONLY $5.99!
Opko Health is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the OPK stock to lose ahead of the earnings release.
ET on Seeking Alpha OPKO Health (OPK) Q2 Earnings and Revenues Surpass Estimates There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term.
The biotechnology company can be reached via phone at 305-575-4100 or via email at Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The stock has a fifty day moving average price of $4.11 and a 200 day moving average price of $2.42. Therefore, we cannot assure you that the information is accurate or complete. Opko Health had a negative net margin of 20.69% and a negative return on equity of 7.96%.
Shares of OPK stock opened at $5.66 on Friday. Hypothetical or simulated performance is not indicative of future results. OPK stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Cito Capital Group LLC, SG Americas Securities LLC, Cambridge Investment Research Advisors Inc., Amalgamated Bank, Strs Ohio, Dupont Capital Management Corp, and Janney Montgomery Scott LLC. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.Here are some recent quotes from research analysts about Opko Health stock: We encourage our investors to invest carefully. There is no guarantee 3 analysts have issued 1 year target prices for Opko Health's shares. Catasys, Inc. (NASDAQ:OTRK) traded at $48.55 at last check on Tuesday, Aug 11, making a downturn move of -18.21% on its previous day's price.
A high percentage of insider ownership can be a sign of company health.Only 23.49% of the stock of Opko Health is held by institutions.Earnings for Opko Health are expected to grow by 66.67% in the coming year, from $0.03 to $0.05 per share.The P/E ratio of Opko Health is -15.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of Opko Health is -15.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Opko Health has a PEG Ratio of 14.07.
The company’s stock has gained about 40.05% over that past 30 days. Looking at the stock we see that its previous close was $3.06 and the... OPKO Health, Inc () Stock Market info Recommendations: Buy or sell OPKO Health stock? Next reporting date: November 4, 2020: EPS forecast (this quarter) $0.04: Annual revenue (last year) $901.9M: Annual profit (last year)-$314.9M: Net profit margin The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. is derived directly from data published by
OPKO Health, Inc. OPK is a diversified healthcare company that could be an interesting play for investors. Top institutional shareholders include Swiss National Bank (0.14%), Principal Financial Group Inc. (0.09%), UBS Group AG (0.06%), Rafferty Asset Management LLC (0.06%), Cambridge Investment Research Advisors Inc. (0.05%) and Strs Ohio (0.04%). Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.Opko Health's stock was trading at $1.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. NYSEMkt Updated Aug 10, 2020 11:59 PM companies or submitted to governmental agencies which we believe are reliable, but are without our On average, they anticipate Opko Health's share price to reach $5.50 in the next twelve months.
Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. The trading delta at closing time to current price is 12.39% .